Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1992-4-23
|
pubmed:abstractText |
An HB prophylaxis vaccination that included a primary and secondary vaccination was carried out on persons working at the university hospital. In the primary vaccination group, the subjects were inoculated the second time with a vaccine derived from human blood plasma obtained from the Kitazato Therapeutic Research Institute. The third time, they were inoculated with a vaccine from the Chemo-Sero Therapeutic Research Institute derived from a second-generation vaccine organized ferment. The vaccine used for the second inoculation group was obtained from the Chemo-Sero Therapeutic Research Institute. Results were summarized as follows: 1) The primary vaccination group: (1) The number of the 153 subjects inoculated with the primary vaccination at the time of the second inoculation, 49 subjects (32%) tested positive for antibodies 3-4 months following inoculation. Thirty-two subjects (20%) tested positive 15-16 months following inoculation with a high rate among females. (2) Among 104 subjects inoculated the third time with the primary vaccination (those who tested negative the second inoculation of the above vaccine), 61 subjects (58.7%) tested positive for antibodies 8-9 months following inoculation with a generally high rate among females. Twenty-eight subjects (26%) tested 15-16 months after inoculation with a high rate among females between 20 and 30 years and among males between 40 and years. 2) The secondary group: Among the 38 subjects who were inoculated the second time with the secondary vaccination, 8 subjects (21%) tested positive for antibodies 5-6 months following inoculation, with a high rate among females in their 20's. 3) The rate of antibodies formation.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
D
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0454-8302
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
25
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
109-14
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2134261-Adult,
pubmed-meshheading:2134261-Age Factors,
pubmed-meshheading:2134261-Antibody Formation,
pubmed-meshheading:2134261-Female,
pubmed-meshheading:2134261-Follow-Up Studies,
pubmed-meshheading:2134261-Hepatitis B,
pubmed-meshheading:2134261-Hepatitis B Antibodies,
pubmed-meshheading:2134261-Humans,
pubmed-meshheading:2134261-Immunization, Secondary,
pubmed-meshheading:2134261-Male,
pubmed-meshheading:2134261-Sex Factors,
pubmed-meshheading:2134261-Vaccination,
pubmed-meshheading:2134261-Viral Hepatitis Vaccines
|
pubmed:year |
1990
|
pubmed:articleTitle |
[Follow-up study on anti-HBs levels in vaccinees after two and three doses of HB vaccine. (2)].
|
pubmed:affiliation |
Department of Clinical Pathology and Clinical Laboratories, Kanagawa Dental College.
|
pubmed:publicationType |
Journal Article,
English Abstract
|